Source: PR Newswire

Press Release: Eli Lilly : Lilly Announces New Clinical Data from Verzenio and Oral SERD Programs at the American Society of Clinical Oncology Annual Meeting

INDIANAPOLIS, June 4, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced new data for the investigational use of Verzenio® (abemaciclib) in high risk early breast cancer, and for its oral selective estrogen receptor degrader (SERD) LY3484356 at the 57th Annual Meeting...

Read full article »

Top Competitors or Alternatives

Missing a competitor? Contribute!

Annual Revenue
David A. Ricks's photo - Chairman & CEO of Eli Lilly

Chairman & CEO

David A. Ricks

CEO Approval Rating


Read more